| 11.10.21 | Sanofi, Roche ally for insulin pen push; Halozyme eyes cell therapy role for drug delivery tech

Click here to subscribe to Fiercebiotech.com

3 years ago

Html
Text

Webinar: The cell therapy divide: How to navigate the challenges of taking clinical-level manufacturing capacity up to commercial scale

Tuesday, November 16 | 11am ET / 8am PT

When your manufacturing process depends on healthcare professionals working with the patients to get the front-end and back-end of the processes exactly right, those professionals need to understand your process unequivocally. We’ll discuss the challenges posed by this new wave of therapies and how the pioneers in the field are tackling them. Register Now.

Today's Rundown

Sanofi, Roche team up to drive adoption of smart insulin pen With subcut Darzalex driving growth, Halozyme eyes role for drug delivery tech in cell therapies With filing in sight, Opiant's nasal opioid overdose drug boards FDA fast track Improving immunotherapy delivery by bringing order to tumor blood vessels Fierce Biotech’s Rotten Tomatoes 2021

Featured Story

Sanofi, Roche team up to drive adoption of smart insulin pen

By Nick Paul Taylor

Sanofi and Roche have joined forces in France, teaming up to drive adoption of a connected add-on for disposable insulin pens. The partners will jointly develop a scientific program for physicians and retail pharmacists around the Biocorp product.

Webinar: A Systems Model of Gene Therapy for Sickle Cell Disease

Tuesday, November 30 | 2pm ET / 11am PT

Stem cell gene therapy is an emerging experimental therapy for SCD with the potential for lifelong cure but it is an expensive multi-step treatment regimen. This webinar is ideal for scientists and decision makers in drug R&D who want to leverage systems pharmacology for drug discovery and development. Register Now.

With subcut Darzalex driving growth, Halozyme eyes role for drug delivery tech in cell therapies

By Nick Paul Taylor

Halozyme Therapeutics has outlined plans to expand use of its Enhanze drug delivery technology, branching out beyond antibodies to cover small molecules and cell therapies.

With filing in sight, Opiant's nasal opioid overdose drug boards FDA fast track

By Nick Paul Taylor

Opiant Pharmaceuticals has landed fast-track designation for its nasal nalmefene formulation, teeing it up to benefit from close communication with the FDA as it prepares to seek approval for the opioid overdose drug in the coming months.

Improving immunotherapy delivery by bringing order to tumor blood vessels

By Nick Paul Taylor

The leaky, disorganized mess of blood vessels that support tumors can stop drugs from reaching their targets and thereby nullify their impact. Recognizing that, researchers have identified a way to bring order to the blood vessels—and thereby enable drugs to reach their targets in the tumor.

Fierce Biotech’s Rotten Tomatoes 2021

By Ben Adams

The biopharma industry has received acclaim during the COVID-19 pandemic. But while some companies have been working hard on life-saving therapies, others' actions have further stained the industry's already shaky reputation.

Webinar: Oral solid dose formulations: Integrating patient centricity into development and lifecycle strategies

Wednesday, December 1, 2021 | 11am ET/ 8am PT

Meeting the increasing demand for patient centricity in drug design is key to your molecule’s success. Learn how to implement development and lifecycle management strategies. Register Now.